Medication progress for Alzheimer's disease

Chinese Journal of Clinical Rehabilitation

Volumn 8, Issue 16, 2004, Pages 3104-3105

  Li, Ke ^a   Wan, Qi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; DONEPEZIL; FREUND ADJUVANT; N METHYL DEXTRO ASPARTIC ACID; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL STUDY; COCHRANE LIBRARY; DEMENTIA; HUMAN; REVIEW;

EID: 3543086754     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Chinese source. 2002, 6(1): 28-9
2. Chinese source. 2002, 6(13): 1906-7
3. Bayer TA, Wirths O, Majtenyi K, et al. Key factors in Alzheimer's disease: β-amyloid precursor protein Processing, metabolism and intraneuronal transport. Brain Pathology 2001; 11: 1-11
4. Scott L, Goa K. Galantamine: a review of its use in Alzheimer's Disease. Drugs 2000; 60: 1095-122
5. Xie W, Stribley JA, Chatonnet A, et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 2000; 293: 896-902
6. Wang XD, Chen XQ, Yang HH, et al. Comparison of the effects of cholinesterase inhibitors on [3H] MK-801 binding in rat cerebral cortex. Neurosci Lett 1999; 272 (1): 21-4
7. Akasofu S, Kosasa T, Kimura M, et al. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol 2003; 472 (1-2): 57-63
8. Chinese source. 2004, 8(1): 74-5
9. Feldman H, Gauthier S, Hecker J, et al. A 24-week, moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20
10. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigimine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56: 441-6
11. Reinsberg B, Doody R, Stoffer A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41
12. In t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21
13. Xiang Z, Ho L, Yemul S, et al. COX-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expression 2002; 10: 271-8
14. Pasinetti G, Pompl P. Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAP Ted? Lancet Neurol 2002; 1: 403-4
15. Aisen P. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 2002; 1: 279-84
16. Sisodia SS, St George-Hyslop PH. Notch GS. Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 2002; 3: 281-90
17. Luo Y, Bolon B, Kahn S, et al. Mice deficient in BACE1, the Alzheimer's secretase, have normal phenotype and abolished-amyloid generation. Nat Neurosci 2001; 4: 31-2
18. Petit A, Bihel F, Alves da Costa C, et al. New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage. Nat Cell Biol 2001; 3:507-11
19. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid- attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7
20. Weiner HL, Lemere CA, Maron R, et al. Nasal administration of amyloid-peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000; 48: 567-79